Publications by authors named "Xin-Ting Li"

Gene therapy has been adapted, from the laboratory to the clinic, to treat retinopathies. In contrast to subretinal route, intravitreal delivery of AAV vectors displays the advantage of bypassing surgical injuries, but the viral particles are more prone to be nullified by the host neutralizing factors. To minimize such suppression of therapeutic effect, especially in terms of AAV2 and its derivatives, we introduced three serine-to-glycine mutations, based on the phosphorylation sites identified by mass spectrum analysis, to the XL32 capsid to generate a novel serotype named AAVYC5.

View Article and Find Full Text PDF

Purpose: Targeting angiogenesis is an attractive strategy for the effective treatment of cancer. This study aimed to investigate the anti-cancer activities of YAP inhibitor verteporfin (VP) in esophageal squamous cell carcinoma (ESCC) cells through its inhibitory effect on tumor angiogenesis.

Methods: Cell proliferation, apoptosis, migration and invasion abilities were estimated by MTT, colony formation, DAPI staining, wound healing and transwell assays, respectively.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Xin-Ting Li"

  • - Xin-Ting Li's recent research focuses on innovative therapeutic strategies in gene therapy and cancer treatment, exploring mechanisms to enhance drug delivery and efficacy in challenging medical conditions.
  • - One study highlights the development of a new adeno-associated virus serotype (AAVYC5) that improves retinal delivery while overcoming neutralizing factors to treat retinopathies effectively.
  • - Another significant finding involves the use of the YAP inhibitor verteporfin, which demonstrates potential in suppressing tumor angiogenesis and overcoming chemoresistance in esophageal squamous cell carcinoma, presenting a promising approach to improve cancer treatment outcomes.